New thiazole-biaryls as small molecule immunomodulators (SMIs) targeting PD-1/PD-L1 axis
{{output}}
Immune Checkpoint Inhibitors (ICIs) targeting the PD-1/PD-L1 axis have improved the clinical outcomes and revolutionized oncology treatment. However, monoclonal antibody (mAb)-based ICIs are limited by high production and treatment cost, poor oral bioavailabil... ...
